Is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease.
Exited Portfolio Company
https://renovacor.com/
Location: United States, Connecticut, Greenwich
Investors 1
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 01.09.2021 | Chardan Healthcare Acquisition 2 Corp. : Announces Stockhold... | NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("C... | marketscre... |
| 14.08.2019 | Renovacor Closes $11 Million Series A Financing to Advance F... | – Funding supports preclinical development through IND submission for its BAG3 gene therapy, the fir... | venturebea... |
| 14.08.2019 | Renovacor Completes $11M Series A Financing Round | Magdalene Cook, MD, President and CEO of Renovacor Renovacor, Inc., a Philadelphia, PA-based precli... | finsmes.co... |